Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
Monday, July 13, 2026 1 min read
Key Takeaway: Charles River Laboratories has partnered with Arovella Therapeutics to provide GMP Next Generation Sequencing services. This collaboration aims to support Arovella in developing an Invariant Natural Killer T cell therapy platform for cancer treatment. The partnership is expected to accelerate progress towards innovative cancer treatment approaches.
Price reaction · baseline $233.41 (2026-07-10 close) · hit pre-market · clean, no other CRL news in the window
day 0 close · peak
-1.6%
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration enhances Arovella's cancer treatment capabilities.
Charles River's GMP NGS services support advanced cell characterization.
The partnership aims to develop an innovative iNKT cell therapy platform.
Full Press Release Details
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA
Frequently Asked Questions
What services is Charles River providing to Arovella?
Charles River is providing Good Manufacturing Practice Next Generation Sequencing services.
What is the goal of Arovella's collaboration with Charles River?
The collaboration aims to develop a unique iNKT cell therapy platform for cancer treatment.
What type of therapy is Arovella focusing on?
Arovella is focusing on Invariant Natural Killer T cell therapy for cancer.
How will the collaboration impact cancer treatment?
The partnership is expected to accelerate progress towards innovative cancer treatment approaches.